The incidence and mortality rate of gastric cancer are the fourth and second highest in the world, respectively as reported by WHO cancer statistics (
1,
2). Recently, it has been reported that the most common form of recurrence in gastric cancer, including all stages, is peritoneal dissemination, followed by local recurrence, hepatic metastasis and distant metastasis in which bone metastasis is rare (
3). However, in the study by Yoo et al., the most common recurrence pattern after peritoneal dissemination was hematogeneous recurrence (26.2%) followed by locoregional recurrence (19.3%) (
5). They also demonstrated that these extra-abdominal patterns of recurrence occurred rarely without evidence of intra-abdominal metastasis (
5). Bone metastasis in gastric cancer is a rare condition and varies from 0 to 17.5 % (
4), although Kobayashi. et al. noted that this rate might be underestimated since bone scintigraphy is not performed as a routine clinical practice (
6). The possible mechanisms of hematogeneous metastasis of gastric cancer are through: 1) the portal vein, 2) the venous system, other than the portal vein and 3) the lymphatic channels into the systemic circulation. Most cases of bone metastasis do not show liver involvement. Since most of the venous drainage from the stomach is via the portal vein and many cases of bone metastasis are associated with lymph node involvement, lymphatic channel drainage into the systemic circulation is the mechanism underlying bone metastasis (
6). Bone metastases from gastric adenocarcinoma are usually osteolytic or less commonly mixed osteolytic-osteosclerotic (
7). Osteosclerotic metastases are even rarer as noted in 2011 by Saito et al. presenting the seventh case of osteosclerotic bone metastasis from gastric cancer in the English-language literature (
3). The spine was the most common metastatic site (66%), followed by the ribs (59%), pelvis (43%), femur (30%) and the skull (22%) (
8). The least frequent metastatic sites were the shoulder girdle (17%), sacroiliac joint (7.2%), humerus (6.0%), sternum (4.2%) and the tibia (3.0%) (
8), while to our knowledge, there is no previous report of the fibula as a site of bone metastasis in gastric adenocarcinoma. The predominance of metastatic disease in flat bones compared to the long bones is likely to be due to the presence of red marrow (
4), supporting this fact that fibula as a long bone would be a rare site of metastasis as is the case in other cancers such as vaginal cancer, carcinoma of uterine cervix, lung cancer and colorectal cancer (
9-
13). On the other hand, as mentioned above, solitary bone metastasis as the sole sign of recurrence after hopefully curative resection without the disease spreading to other organs is much rarer (
4). There is limited value for radiographic evaluation of bone metastases as symptoms caused by bone metastases frequently occur before being detectable by radiography whereas bone scintigraphy is generally accepted as the initial method of choice for bone metastasis assessment (
6). Bone scintigraphy will show the extent of osseous lesions and it is also useful for demonstrating singularity versus multiplicity of the lesions and to identify asymptomatic lesions. Isotope scans often reveal more extensive lesions than those suggested by initial radiographs (
13).
Usually, radiotherapy is sufficient in most cases of bone metastasis distal to the knee, but pain can be unremitting and resistant to radiotherapy. Options for treatment include local curettage with either bone grafting or cementation or below knee amputation (
13). In some reported cases, surgical resection of the solitary bone lesion was accompanied with an acceptable survival (
10,
14,
15). Our patient underwent surgical resection of the lesion together with radiotherapy and chemotherapy. The current patient is an unusual case of gastric adenocarcinoma with solitary bone metastasis to the fibula as the first and sole sign of recurrence. In spite of rarity, solitary bone metastasis to leg bones should be considered in the differential diagnoses in patients presenting with new onset of leg pain and a history of distant primary tumor such as gastric adenocarcinoma and it might be better to exclude this possibility first to avoid serious consequences of early misdiagnosis.